D. Singh (Manchester, United Kingdom), A. Papi (Ferrara, Italy)
Late Breaking Abstract - Impact of COPD symptom-related attacks on quality of life and exacerbations
G. Ferguson (Farmington Hills, United States of America), I. Gilbert (Wilmington, United States of America), R. Lamarca (Barcelona, Spain), A. Aksomaityte (London, United Kingdom), D. Lythgoe (London, United Kingdom), T. Skärby (Gothenburg, Sweden), L. Nordenmark (Gothenburg, Sweden), F. Trudo (Wilmington, United States of America)
|    |
A randomized trial to determine the effect of glycopyrrolate/formoterol on exercise tolerance in COPD: influence of dynamic hyperinflation and dead space ventilation.
W. Stringer (Torrance, CA, United States of America), J. Porszasz (Torrance, CA, United States of America), M. Von Plato (Torrance, CA, United States of America), A. Khosrovi-Eghbal (Torrance, CA, United States of America), M. Zopey (Torrance, CA, United States of America), M. Cao (Torrance, CA, United States of America), A. Soriano (Torrance, CA, United States of America), R. Calmelat (Torrance, CA, United States of America), H. Rossiter (Torrance, CA, United States of America), A. Leyva (Torrance, CA, United States of America), S. Siddiqui (Gaithersburg, MD, United States of America), S. Rennard (Cambridge, United Kingdom), R. Casaburi (Torrance, CA, United States of America)
| |
Analysis of IMPACT: is one blood eosinophil count measurement sufficient to predict ICS treatment response in COPD?
M. Bafadhel (Oxford, United Kingdom), N. Barnes (Brentford and London, United Kingdom), S. Bourke (North Shields and Newcastle, United Kingdom), C. Compton (Brentford, United Kingdom), G. Criner (Philadelphia, United States of America), M. Dransfield (Birmingham, AL, United States of America), D. Halpin (Exeter, United Kingdom), M. Han (Ann Arbor, MI, United States of America), B. Hartley (Twickenham, United Kingdom), C. Jones (Research Triangle Park, NC, United States of America), P. Lange (Copenhagen and Herlev, Denmark), S. Lettis (Uxbridge, United Kingdom), D. Lipson (Collegeville and Philadelphia, United States of America), D. Lomas (London, United Kingdom), N. Martin (Brentford and Leicester, United Kingdom), F. Martinez (New York, NY, United States of America), R. Van Der Valk (Brentford, United Kingdom), R. Wise (Baltimore, MD, United States of America), D. Singh (Manchester, United Kingdom)
| |
SYSTEMIC EFFECT OF CONTINUOUS TREATMENT WITH AZITHROMYCYN IN PATIENTS WITH SEVERE COPD AND FREQUENT EXACERBATIONS
E. Cuevas Sales (Hospitalet de Llobregat, Barcelona, Spain), D. Huertas Almela (Satn Pere de Ribes, Barcelona, Spain), Y. Pascual González (Hospitalet de Llobregat, Barcelona, Spain), M. López Sánchez (Hospitalet de Llobregat, Barcelona, Spain), C. Montón Soler (Sabadell, Barcelona, Spain), X. Pomares Amigó (Sabadell, Barcelona, Spain), A. Marin Tàpia (Badalona, Barcelona, Spain), M. García Núñez (Sabadell, Barcelona, Spain), S. Martí Martí (Hospitalet de Llobregat, Barcelona, Spain), S. Santos Pérez (Hospitalet de Llobregat, Barcelona, Spain)
|  |
Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD
D. Singh (Manchester, United Kingdom), M. Nandeuil (Bios Colombes, France), C. Pigeon-Francisco (Bios Colombes, France), A. Emirova (Bios Colombes, France), D. Santoro (Parma, Italy), S. Biondaro (Parma, Italy), M. Govoni (Parma, Italy), S. Petruzzelli (Parma, Italy)
| |
Antiviral biomarkers are upregulated in sputum cells following administration of inhaled interferon beta to COPD patients
S. Reynolds (Southampton, United Kingdom), K. Lunn (Southampton, United Kingdom), R. Beegan (Southampton, United Kingdom), V. Tear (Southampton, United Kingdom), P. Monk (Southampton, United Kingdom)
| |
Clinical impact of a non-typeable Haemophilus influenzae (NTHi) adjuvanted vaccine in adults with chronic obstructive pulmonary disease (COPD)
D. Riccucci (Siena, Italy), T. Wilkinson (Southampton, United Kingdom), S. Schembri (Dundee, United Kingdom), C. Brightling (Leicester, United Kingdom), N. Bakerly (Salford, United Kingdom), K. Lewis (Swansea, United Kingdom), W. Macnee (Edinburgh, United Kingdom), L. Rombo (Uppsala, Sweden), M. Allen (Stoke-on-Trent, United Kingdom), P. Walker (Liverpool, United Kingdom), D. Casula (Siena, Italy), P. Moris (Rixensart, Belgium), S. Schoonbroodt (Rixensart, Belgium), M. Testa (Siena, Italy), A. Arora (Siena, Italy)
| |
Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, provides effective bronchodilation when administered by dry powder inhaler in COPD
T. Rheault (London, United Kingdom), J. Boscia (Union, SC, United States of America), B. Maurer (London, United Kingdom), K. Rickard (London, United Kingdom)
| |